• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

fredhutchinsoncancerresearchercenter

Study: Biodegradable nanoparticles reprogram immune cells to fight cancer

April 18, 2017 By Sarah Faulkner

Fred Hutchinson Cancer Researcher Center logo

Researchers at the Fred Hutchinson Cancer Researcher Center have reportedly engineered biodegradable nanoparticles that can genetically reprogram immune cells to recognize and destroy cancer cells, without taking the immune cells out to manipulate them. The team demonstrated their idea in a proof-of-principle study published in Nature Nanotechnology. They showed that reprogrammed immune cells, or T cells, help […]

Filed Under: Featured, Immunotherapy, Nanoparticles, Oncology, Preclinical Trials, Research & Development Tagged With: fredhutchinsoncancerresearchercenter

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS